Abstract
Purpose :
To investigate the retreatment incidence and its risk factors within 60 months after photodynamic therapy (PDT) combined with intravitreal ranibizumab (IVR) for treatment-naïve polypoidal choroidal vasculopathy (PCV).
Methods :
We retrospectively reviewed the medical records of 61 eyes from 60 patients with PCV, who were followed-up for at least 12 months after the combination therapy. Retreatment including IVR or the combination therapy was conducted if residual or recurrence exudative changes were present. We investigated whether baseline clinical and genetic factors including ARMS2 A69S and CFH I62V, were associated with retreatment after the initial treatment.
Results :
During follow-up period(mean:44±13 months, median 48 months),46 eyes(75.4%) received the retreatment. Survival analysis revealed that survival proportion was 59%, 41%, 31%, 24%, and 20% at 12-, 24-, 36-, 48- and 60-month visit, respectively. Median and mean retreatment free period was 15.0(95% confidence interval (CI):7.4-22.7) and 24.9(95% CI: 19.3-30.6) months, respectively. Mean best-corrected visual acuity (BCVA) significantly improved throughout follow-up periods except at 48-month visit. Cox regression analysis revealed that older age (P=0.011, hazard ratio 1.05 confidence interaval1.01-1.10) and male (P=0.018, hazard ratio 2.47 confidence interval 1.10-5.61) was associated with retreatment.
Conclusions :
Visual outcomes 5 years after PDT combined with IVR were relatively favorable. Retreatment was required for about 80% eyes within 60 months after the combined therapy for PCV. Retreatment was associated with older age and male.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.